Skip to content

Cerebrolysin’s evidence from TBI research – Treat early, reduce acute and post-acute complications

ON DEMAND Published on April 17, 2024 at 13:00 - 14:00 CET

Treating secondary damage symptoms occurring short-and longterm after neurotrauma is an essential task of critical care specialists working in the ER and ICU. Pharmacological agents indicated to save lives after polytrauma or isolated head trauma are globally accepted medications. Cerebrolysin can nowadays be included into the globally acknowledged treatment bundles due to the strong evidence provided from the CAPTAIN trials. The speakers will discuss how the evidence lead to the inclusion into hospital-internal standard treatment strategies as well as first acknowledgement in important  guidelines.

Duration: 60 minutes

Languages: Webinar will be held in English language incl. subtitles if requested. Furthermore Russian and Ukrainian simultaneous translation will be offered.


Mark Bayley

UHN-Toronto Rehabilitation Institute, University of Toronto, Canada

Bettina Pfausler

Department of neurological intensive care medicine and neuroinfectiology, Medical University Innsbruck, Austria

Harald Widhalm

Clinical Department of Trauma Surgery, Medical University of Vienna, Austria